- Home
- FORA vs KRRO Comparison
FORA vs KRRO Comparison
Compare FORA & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FORA | KRRO |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.4M | 58.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | FORA | KRRO |
|---|---|---|
| Price | $2.13 | $7.89 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $74.17 |
| AVG Volume (30 Days) | 30.1K | ★ 287.0K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,106,911.00 | $7,371,000.00 |
| Revenue This Year | $47.82 | $144.83 |
| Revenue Next Year | $10.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 37.47 | N/A |
| 52 Week Low | $1.64 | $5.20 |
| 52 Week High | $4.03 | $55.89 |
Technical Indicators
Market Signals| Indicator | FORA | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 49.14 | 34.66 |
| Support Level | $2.06 | $7.73 |
| Resistance Level | $2.12 | $8.14 |
| Average True Range (ATR) | 0.05 | 0.51 |
| MACD | 0.00 | 0.71 |
| Stochastic Oscillator | 64.33 | 30.92 |
Price Performance
Historical ComparisonAbout FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.